Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Systemic sclerosis
•
Interstitial lung disease
•
Scleroderma
•
Pulmonary
Would nintedanib offer benefit to a patient with scleroderma (Anti-Th/To+/SSA+) who has CT chest with typical UIP pattern?
Related Questions
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
In light of the RECITAL study, would rituximab be a reasonable choice in a patient with PL-12 antibodies, rapidly progressive pulmonary disease with organizing pneumonia on biopsy?
How do you approach symptom control in a patient with diffuse cutaneous systemic sclerosis (dcSSc) and rapidly progressive skin disease?
What considerations do you take when using prednisone in patients with systemic sclerosis?
What dose and duration of steroid therapy do you employ while starting mycophenolate in an outpatient with relatively stable CTD-ILD?
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency, would you recommend treatment with endovenous laser/ablation?
In a patient with antisynthetase syndrome (Jo-1+, ILD, and myositis) treated with IVIG, mycophenolate, and tacrolimus, would you stop the IVIG after lung transplant? Myositis has not been active. What is the risk of recurrence of ILD after lung transplant?
How do you approach management of ILD in the presence of weakly positive RF and ANA but no other objective systemic findings of connective tissue disease?
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
